Balanced news tone
News Sentiment
IMVT sentiment intelligence
Immunovant Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
61 relevant articles
News tone and price action are not far from neutral.
82/100 classification confidence.
directly relevant articles
high-authority source matches
+2.4% over one week, +18.1% over four weeks, trend active, and materially above fair value.
Form 4 Immunovant Inc For: 10 July By Investing.com
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
82/100 classification
One-week reaction
2.4%
Price confirming higher
Trend fit
Trend active
18.1% over four weeks
Fair value
50.6%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
16
Neutral
37
Negative
8
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Investing.com Nigeria
Direct company coverage
Form 4 Immunovant Inc For: 10 July By Investing.com
This article from Investing.com announces the filing of a Form 4 for Immunovant Inc. on July 10th. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by
- Tone
- Negative 31/100
- Event
- Market update
- Published
- 11 Jul 2026 17:10
- Source
- Investing.com Nigeria
Investing.com
Direct company coverage
Immunovant CTO Jay Stout sells $137,924 in IMVT stock
Immunovant's CTO, Jay Stout, sold 3,487 shares of IMVT stock totaling $137,924. These were "sell to cover" transactions to meet tax obligations from vested restricted stock units, not discretionary sales. The stock has seen a significant 135% gain over the past year, though Inves
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 05:09
- Source
- Investing.com
Investing.com
Direct company coverage
Immunovant chief legal officer Van Tuyl sells $47,702 in stock
Immunovant's Chief Legal Officer, Christopher Van Tuyl, recently sold 1,206 shares of company stock for a total of $47,702 to cover tax withholding obligations related to restricted stock units. Following these transactions, Van Tuyl still holds 179,391 shares. The stock has seen
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 21:09
- Source
- Investing.com
Investing.com
Direct company coverage
Immunovant COO Melanie Gloria sells $80,531 in shares
Immunovant COO Melanie Gloria sold $80,531 worth of company common stock on July 8, 2026, to cover tax withholding obligations related to the vesting of restricted stock units. Following these transactions, Ms. Gloria directly holds 222,357 shares. The sale occurred while Immunov
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 20:09
- Source
- Investing.com
Stock Titan
Direct company coverage
Immunovant (IMVT) COO offloads 2,036 shares to cover RSU tax withholding
Immunovant, Inc.'s Chief Operating Officer, Gloria Melanie, sold 2,036 shares of common stock on July 8, 2026. These sales were not discretionary but were mandated "sell to cover" transactions to meet tax withholding obligations from the vesting of restricted stock units (RSUs).
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 20:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Immunovant (IMVT) CTO offloads 3,487 shares in mandated RSU tax-withholding sales
Immunovant's Chief Technology Officer, Jay S. Stout, sold 3,487 shares of IMVT common stock on July 8, 2026. These sales were non-discretionary "sell to cover" transactions to meet tax withholding obligations due to the vesting of restricted stock units (RSUs). The sales occurred
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 20:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Immunovant (IMVT) legal chief sells 1,206 shares in tax “sell to cover”
Christopher Van Tuyl, Immunovant's Chief Legal Officer, sold 1,206 shares of common stock on July 8, 2026, in a mandatory "sell to cover" transaction. This sale, totaling approximately $47,702, was executed to satisfy tax withholding obligations following the vesting of previousl
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 20:09
- Source
- Stock Titan
Moomoo
Direct company coverage
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $53
LifeSci Capital has reiterated its Buy rating for Immunovant (IMVT.US) and increased its price target for the stock to $53. This indicates a continued positive outlook from the firm regarding Immunovant's financial prospects and market valuation.
- Tone
- Positive 73/100
- Event
- Analyst action
- Published
- 10 Jul 2026 05:39
- Source
- Moomoo
Ad-hoc-news.de
Direct company coverage
Immunovant Inc explores long term growth paths as autoimmune pipeline advances
Immunovant Inc is focusing on developing therapies for autoimmune diseases and expanding its pipeline. The company's long-term growth is dependent on successful clinical trials
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jul 2026 12:10
- Source
- Ad-hoc-news.de
Investing.com
Direct company coverage
Immunovant stock hits 52-week high at 39.28 USD
Immunovant Inc. (IMVT) stock reached a new 52-week high of $39.28, marking a 130.79% increase over the past year. This surge is fueled by positive results from its Phase 2 rheumatoid arthritis study of IMVT-1402, with analysts from H.C. Wainwright, BofA Securities, and Stifel rai
- Tone
- Positive 72/100
- Event
- Earnings
- Published
- 08 Jul 2026 04:40
- Source
- Investing.com
Stock Traders Daily
Direct company coverage
Understanding Momentum Shifts in (IMVT)
This article analyzes Immunovant Inc. (IMVT) using AI-generated signals, indicating a strong overweight bias across all time horizons. It provides detailed trading strategies for different risk profiles, including position, momentum breakout, and risk hedging, along with multi-ti
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 08 Jul 2026 04:40
- Source
- Stock Traders Daily
Investing.com South Africa
Direct company coverage
Immunovant stock hits 52-week high at 39.28 USD By Investing.com
Immunovant Inc. (IMVT) stock reached a new 52-week high of $39.28, marking a 130.79% increase over the past year and achieving a market capitalization of $8.01 billion. This surge is supported by positive analyst ratings and promising results from its Phase 2 rheumatoid arthritis
- Tone
- Positive 73/100
- Event
- Earnings
- Published
- 07 Jul 2026 23:40
- Source
- Investing.com South Africa
AD HOC NEWS
Direct company coverage
Immunovant Inc outlines its autoimmune drug pipeline as investors watch clinical milestones
Immunovant Inc is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases using targeted antibody inhibition. The company's pipeline includes treatments for neuromuscular disorders and dermatologic autoimmune diseases, with development h
- Tone
- Positive 63/100
- Event
- Market update
- Published
- 07 Jul 2026 14:13
- Source
- AD HOC NEWS
Stock Titan
Direct company coverage
Immunovant (IMVT) CEO settles CVARs with small tax-related share sale
Immunovant, Inc. CEO Eric Venker reported the settlement of 92,188 vested capped value appreciation rights (CVARs) into common stock on July 1, 2026, after meeting service, performance, and knock-in conditions. Concurrently, he disposed of 86,629 shares to the issuer and sold 3,0
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 04:40
- Source
- Stock Titan
Investing.com Canada
Direct company coverage
Immunovant CEO Eric Venker sells $118,980 of IMVT stock By Investing.com
Immunovant CEO Eric Venker recently sold 3,092 shares of Immunovant (NASDAQ:IMVT) common stock for approximately $118,980. This "sell to cover" transaction was executed to fulfill tax withholding obligations tied to the vesting of Capped Value Appreciation Rights (CVARs). The sal
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 04:09
- Source
- Investing.com Canada
Investing.com
Direct company coverage
Immunovant CEO Eric Venker sells $118,980 of IMVT stock
Immunovant CEO Eric Venker sold 3,092 shares of company common stock worth $118,980 to cover tax withholding obligations related to the vesting of Capped Value Appreciation Rights (CVARs). The transaction occurred on July 2, 2026, with the shares sold at $38.48 each. Following th
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 06 Jul 2026 22:13
- Source
- Investing.com
Investing.com Canada
Direct company coverage
Form 4 Immunovant Inc For: 6 July By Investing.com
This article announces the filing of a Form 4 for Immunovant Inc. on July 6. Form 4 filings typically report changes in beneficial ownership of a company's securities by insiders. The article provides the title of the filing but no further details about its content.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 21:09
- Source
- Investing.com Canada
Finviz
Direct company coverage
IMVT - Immunovant Inc Revenue Breakdown
This article provides a detailed financial overview of Immunovant Inc. (IMVT), covering key metrics such as market cap, income, sales, stock performance, and analyst recommendations. It highlights the company's valuation ratios, insider and institutional ownership, and profitabil
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jul 2026 11:09
- Source
- Finviz
Sahm
Direct company coverage
Chief Technology Officer Of Immunovant Sold 53% Of Their Shares
Immunovant Inc.'s Chief Technology Officer, Jay Stout, recently sold US$1.5 million worth of stock, representing 53% of his holding. While insider selling at the current price isn't as concerning as selling at a lower price, there has been no insider buying in the last year. Insi
- Tone
- Negative 35/100
- Event
- Market update
- Published
- 04 Jul 2026 03:39
- Source
- Sahm
Finviz
Direct company coverage
IMVT - Immunovant Inc Options
This page provides a detailed financial overview of Immunovant Inc (IMVT), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It also lists key statistics such as EPS, insider and institutional ownership, profitability metr
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 03 Jul 2026 02:39
- Source
- Finviz
Moomoo
Direct company coverage
Citi Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $61
Citi has reiterated its Buy rating for Immunovant (IMVT.US) and increased the target price to $61. This indicates a continued positive outlook from Citi on the company's stock performance.
- Tone
- Positive 71/100
- Event
- Analyst action
- Published
- 30 Jun 2026 14:39
- Source
- Moomoo
Moomoo
Direct company coverage
Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing
An insider at Immunovant recently sold shares valued at $1,532,309, as disclosed in a recent SEC filing. This transaction could be of interest to investors tracking insider activity within the company. Further details would typically be available in the full SEC document.
- Tone
- Negative 32/100
- Event
- Market update
- Published
- 29 Jun 2026 08:13
- Source
- Moomoo
Investing.com
Direct company coverage
Immunovant CTO Jay Stout sells $1.53m in company stock
Immunovant CTO Jay Stout sold 40,000 shares of the company’s common stock for over $1.53 million on June 26, 2026. This sale occurred while Immunovant shares were trading near their 52-week high, with InvestingPro analysis suggesting the stock is overvalued. Despite this insider
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 13:40
- Source
- Investing.com
Stock Titan
Direct company coverage
Immunovant (IMVT) CTO Jay S. Stout sells 40,000 shares in open-market trades
Immunovant, Inc. CTO Jay S. Stout reported selling a total of 40,000 shares of the company's common stock in two open-market transactions on June 26, 2026. The shares were sold at weighted average prices of $38.18 and $38.94 per share, totaling approximately $1.53 million. Follow
- Tone
- Negative 14/100
- Event
- Market update
- Published
- 27 Jun 2026 11:39
- Source
- Stock Titan
GuruFocus
Direct company coverage
Insider Sell: Melanie Gloria Sells 17,714 Shares of Immunovant I
Melanie Gloria, Chief Operating Officer at a subsidiary of Immunovant Inc (IMVT), sold 17,714 shares of the company on June 26, 2026. Following this transaction, Gloria now owns 224,393 shares. Immunovant Inc is a clinical-stage biopharmaceutical company, and this sale marks part
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 27 Jun 2026 02:39
- Source
- GuruFocus
TradingView
Direct company coverage
Price to book forward of Immunovant, Inc. – NASDAQ:IMVT
This article from TradingView focuses on the "Price to book forward" financial metric for Immunovant, Inc. (NASDAQ: IMVT). It is primarily a data page, displaying the period, value, and change for this specific financial indicator related to the biotechnology company. The content
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 01:13
- Source
- TradingView
Investing.com
Direct company coverage
Immunovant CFO Tiago Girao sells $384,600 in company stock
Immunovant (NASDAQ:IMVT) CFO Tiago Girao sold 10,000 shares of company stock for approximately $384,600 after exercising stock options for the same number of shares. The sale occurred while Immunovant shares were trading near their 52-week high, having delivered a 137% return ove
- Tone
- Positive 59/100
- Event
- Market update
- Published
- 27 Jun 2026 00:39
- Source
- Investing.com
Investing.com
Direct company coverage
Immunovant chief legal officer sells $682,886 in stock
Christopher Van Tuyl, Chief Legal Officer at Immunovant, Inc. (NASDAQ:IMVT), sold 17,824 shares of company stock for $682,886 on June 26, 2026, after exercising stock options. The sales occurred while the stock was near its 52-week high, following a significant 137% gain over the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 00:39
- Source
- Investing.com
Stock Titan
Direct company coverage
Immunovant (IMVT) Chief Legal Officer sells 17,824 shares after option exercise
Immunovant, Inc.'s Chief Legal Officer, Christopher Van Tuyl, exercised options for 17,824 shares at $15.20 each and subsequently sold all these shares in open-market transactions for approximately $38.19 to $38.96 per share. Following these transactions, Van Tuyl directly holds
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 00:10
- Source
- Stock Titan